NASDAQ:SESN
Delisted
Sesen Bio Stock News
$0.629
+0 (+0%)
At Close: Jun 06, 2023
Top Penny Stocks to Buy Right Now? 4 For Your June Watchlist
05:33pm, Monday, 17'th May 2021
Making a penny stocks watchlist for June? Take a look at these 3 The post Top Penny Stocks to Buy Right Now?
Sesen Bio, Inc. (SESN) CEO Thomas Cannell on Q1 2021 Results - Earnings Call Transcript
11:36am, Monday, 10'th May 2021
Sesen Bio, Inc. (SESN) CEO Thomas Cannell on Q1 2021 Results - Earnings Call Transcript
Sesen Bio Reports First Quarter 2021 Financial Results and Commercial Launch Readiness Update in the US for Vicineum™
07:30am, Monday, 10'th May 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported ope
Penny Stocks To Watch For May 2021
11:15am, Sunday, 09'th May 2021
Hot penny stocks to watch this month. The post Penny Stocks To Watch For May 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Sesen Bio: Long-Term And Short-Term Potential In Advance Of Its First PDUFA
02:04pm, Friday, 07'th May 2021
Sesen Bio is seeking an accelerated approval for its NMIBC therapy, Vicineum, and the PDUFA date is coming up soon on Aug. 18.
Sesen Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 16'th Apr 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported the
Sesen: Vicineum Could Be The Ultimate Catalyst
10:44am, Monday, 29'th Mar 2021
Sesen: Vicineum Could Be The Ultimate Catalyst
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported ope
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced th
Sesen Bio: Vicineum's Priority Review Provides Conviction To Hold Through PDUFA Date
01:48pm, Monday, 22'nd Feb 2021
The FDA has provided Vicineum a priority review and an August 2021 PDUFA date. Following the headline, Sesen Bio's share price spiked to a new 52-week high. Now with an accelerated timeline and no AdC
Sesen Bio: Problems Of Main Competitor Make Vicinium More Attractive
08:57am, Sunday, 21'st Feb 2021
Sesen Bio's vicinium is targeting a form of NMIBC. Its chief competitor is adstiladril, and its current position with the FDA is a bit vague.
Why Hepion Pharma, Sesen Bio And More Are Moving Today
11:44am, Tuesday, 16'th Feb 2021
Hepion Pharmaceuticals (NASDAQ: HEPA) shares are trading lower Tuesday after the company priced its 44.2 million share common stock offering at $2 per share. Hepion Pharmaceuticals Inc is engaged in t
Sesen Bio's Vicineum US Application For Bladder Cancer Accepted For Review; Shares Spike
09:13am, Tuesday, 16'th Feb 2021
Under priority review status, the FDA has accepted Sesen Bio Inc's (NASDAQ: SESN) marketing application for review seeking approval for Vicineum for the treatment of high-risk, BCG-unresponsive non
Dr. Thomas Cannell, President and CEO of Sesen Bio, to Host Conference Call to Provide a Business Update
04:30pm, Friday, 12'th Feb 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced th
Why Sesen Bio Stock Is Soaring Today
11:37am, Monday, 25'th Jan 2021
An analyst is very bullish about the biotech stock.
